Wanna make money (or lose it)?

In this interactive panel at next week’s London SynBioBeta Conference, synthetic biology investors will share their experiences in funding companies based in the U.K., Europe and the USA

Here’s a list of five investors who are betting big on synthetic biology:Karl Handelsman from Codon Capital
 is one of the earliest investors and biggest proponents of the field. He has been placing bets for over a decade. He’s made investments in Bolt Threads, Ceratotech, Antheia, Epibiome and will be chairing the panel next week.

Spencer Adler has partnered with Rob Carlson, author of Biology is Technology and a frequent contributor to the SynBioBeta blog, and Rik Wehbring to form Bioeconomy Capital. The team invests in early stage synbio companies such as Synthace and Riffyn.

Andy Smith, a PhD in molecular biology who started in chemical giant ICI and pharma company SmithKline Beecham (now part of GSK), now uses his deep background to deploy capital for Mann Bioinvest. Started in 2012 by Jim Mellon, one of Britain’s richest men, the firm is looking to capitalize on the growing opportunities in the biopharma sector.

Oliver Sexton is investment manager of the £24 million Rainbow Seed Fund, a fund backed by ten UK publicly-funded research organisations and the UK Department of Business, Innovation and Skills. The fund was originally established in 2002 and bolstered in 2013 with an additional £10 million to support the commercialization of synthetic biology technologies spun out of UK universities.